Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 7,024 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Volunteers. Clear all

Conditions: Transfusion Related Complication
Interventions: SNO, Normal Saline, Red Blood Cell; Drug
Lead sponsor: James Reynolds; Other
Eligibility: 18 Years to 35 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepatic Impairment, Healthy
Interventions: ONO-2745 /CNS 7056; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 3
States / cities: Anaheim, California • Orlando, Florida • South Miami, Florida

Conditions: Healthy
Interventions: LY3471851, Placebo, Levocetirizine; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Escherichia Coli Infection
Interventions: Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Thrombocytopenia
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Disease, Healthy
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Genetic Predisposition to Disease, Healthy Volunteers
Interventions: Sirolimus; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 45 Years to 65 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Respiratory Physiology, Respiratory Insufficiency, Breathing Patterns
Interventions: Breathing Patterns; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Adult Volunteers
Interventions: Drug: OP0201, Drug: Placebo; Combination Product
Lead sponsor: Novus Therapeutics, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years to 35 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Freeze Dried Plasma in Healthy Volunteers
Interventions: Autologous Freeze Dried Plasma (FDP), Fresh Frozen Plasma (FFP); Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Participants
Interventions: midazolam, clofutriben once daily for 16 days, 2 single oral doses of prednisolone; Drug
Lead sponsor: Sparrow Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Schizophrenia
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Pirtobrutinib, Placebo, Moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Healthy Volunteer
Interventions: varegacestat; Drug
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Methamphetamine Abuse
Interventions: normal saline, ch-mAb7f9; Biological
Lead sponsor: InterveXion Therapeutics, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Subjects, Pharmacokinetics of ASP015K
Interventions: ASP015K, verapamil; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Subjects
Interventions: Ziresovir, Placebo; Drug · Other
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Refractory Chronic Cough
Interventions: 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]; Drug
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida

Conditions: Healthy Volunteer, Opioid-use Disorder
Interventions: INDV-2000, Placebo, SUBOXONE® sublingual film; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas

Conditions: Healthy Subjects
Interventions: Sativex® (Treatment A), Sativex® and fluconazole concomitantly (Treatment B); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy Male Volunteers
Interventions: Somatrogon; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion

An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

A Phase I Study of LY3471851 in Healthy Participants

Normal Control Cohort Sample Bank

Effect of Surface Electrical Stimulation on Movement of the Larynx

Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus

Magnetic Resonance Imaging at Different Levels of Magnetic Intensity

This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults

Investigation of Efficiency of Breathing With Different Breathing Patterns

Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

Biology of the Oral Epithelium of E-Cigarette Smokers

Ascending Doses of Autologous FDP vs FFP

Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone

Imaging Cannabinoid CB1 Receptors in Schizophrenia

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

A Phase 1 Mass Balance Study of Varegacestat

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.

A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations